Bulletin
Investor Alert

Pfizer Inc.

NYS: PFE

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Feb 26, 2021, 7:59 p.m.

PFE
/zigman2/quotes/202877789/composite

$

33.55

Change

+0.06 +0.18%

Volume

Volume 1.70m

Quotes are delayed by 20 min

/zigman2/quotes/202877789/composite

Previous close

$ 33.82

$ 33.49

Change

-0.33 -0.98%

Day low

Day high

$33.36

$33.90

Open

52 week low

52 week high

$26.41

$43.08

Open

Company Description

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commerc...

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Valuation

P/E Current

19.61

P/E Ratio (with extraordinary items)

19.72

P/E Ratio (without extraordinary items)

21.56

Price to Sales Ratio

4.95

Price to Book Ratio

3.24

Price to Cash Flow Ratio

14.39

Enterprise Value to EBITDA

17.05

Enterprise Value to Sales

5.65

Total Debt to Enterprise Value

0.17

Efficiency

Revenue/Employee

533,860.00

Income Per Employee

88,981.00

Receivables Turnover

5.03

Total Asset Turnover

0.26

Liquidity

Current Ratio

1.35

Quick Ratio

1.04

Cash Ratio

0.47

Profitability

Gross Margin

71.21

Operating Margin

21.52

Pretax Margin

17.89

Net Margin

16.67

Return on Assets

4.34

Return on Equity

11.05

Return on Total Capital

8.14

Return on Invested Capital

6.93

Capital Structure

Total Debt to Total Equity

65.26

Total Debt to Total Capital

39.49

Total Debt to Total Assets

26.76

Long-Term Debt to Equity

60.48

Long-Term Debt to Total Capital

36.60

Officers and Executives

Name Age Officer Since Title
Dr. Albert Bourla 57 2005 Director, Chief Executive & Operating Officer
Mr. Frank A. D'Amelio 61 2007 Chief Financial Officer & EVP-Business Operations
Ms. Lidia L. Fonseca 50 - Chief Technology Officer & EVP
Dr. Monika A. Vnuk - 2008 Vice President-Worldwide Business Development
Dr. Margaret McLoughlin 56 2014 Executive Director-World Wide Business Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
02/22/2021 William R. Carapezzi
Executive Vice President
1,410   Derivative/Non-derivative trans. at $34.26 per share. 48,306
02/22/2021 Payal Sahni
Executive Vice President
1,172   Derivative/Non-derivative trans. at $34.26 per share. 40,152
02/22/2021 Jennifer B. Damico
SVP & Controller
884   Derivative/Non-derivative trans. at $34.26 per share. 30,285
01/31/2021 Lidia L. Fonseca
Executive Vice President
6,749   Derivative/Non-derivative trans. at $35.9 per share. 242,289
12/29/2020 John D. Young
Group President
10,607   Derivative/Non-derivative trans. at $37.05 per share. 392,989
12/16/2020 Rady A. Johnson
Executive Vice President
661   Gift at $0 per share. 0
12/16/2020 Angela Hwang
Group President
12,970   490,784
11/09/2020 Sally Susman
Executive Vice President
43,662   Disposition at $41.94 per share. 1,831,184
11/09/2020 Albert Bourla
Chairman & CEO; Director
132,508   Disposition at $41.94 per share. 5,557,385
08/06/2020 Ronald E. Blaylock
Director
1,000   Acquisition at $38.62 per share. 38,620
08/06/2020 Ronald E. Blaylock
Director
1,000   Acquisition at $38.69 per share. 38,690
08/06/2020 Ronald E. Blaylock
Director
1,500   Acquisition at $38.51 per share. 57,765
08/06/2020 Ronald E. Blaylock
Director
2,500   Acquisition at $38.56 per share. 96,400
08/06/2020 Ronald E. Blaylock
Director
3,000   Acquisition at $38.55 per share. 115,650
08/06/2020 Ronald E. Blaylock
Director
4,000   Acquisition at $38.49 per share. 153,960
06/05/2020 Jennifer B. Damico
SVP & Controller
2,181   Disposition at $36.13 per share. 78,799
05/18/2020 Mikael Dolsten
President R&D
24,242   Disposition at $37.79 per share. 916,105
05/18/2020 Mikael Dolsten
President R&D
17,357   Disposition at $37.78 per share. 655,747
05/18/2020 Mikael Dolsten
President R&D
16,840   Disposition at $37.8 per share. 636,552
05/18/2020 Mikael Dolsten
President R&D
14,727   Disposition at $37.77 per share. 556,238
05/18/2020 Mikael Dolsten
President R&D
9,700   Disposition at $37.75 per share. 366,175
05/18/2020 Mikael Dolsten
President R&D
6,470   Disposition at $37.81 per share. 244,630
05/18/2020 Mikael Dolsten
President R&D
5,517   Disposition at $37.76 per share. 208,321
05/18/2020 Mikael Dolsten
President R&D
500   Disposition at $37.82 per share. 18,910
04/29/2020 John D. Young
Group President
7,910   Gift at $0 per share. 0
04/29/2020 Douglas M. Lankler
Executive Vice President
57,099   Disposition at $37.83 per share. 2,160,055
04/29/2020 Douglas M. Lankler
Executive Vice President
7,901   Disposition at $38.01 per share. 300,317
04/29/2020 Rady A. Johnson
Executive Vice President
13,125   Disposition at $38.36 per share. 503,475
04/29/2020 Dawn Rogers
Executive Vice President
13,000   Disposition at $38.13 per share. 495,690
04/29/2020 Jennifer B. Damico
SVP & Controller
2,181   Disposition at $38.35 per share. 83,641
02/28/2020 Frank A. D'Amelio
Executive Vice President
89,721   Derivative/Non-derivative trans. at $36.45 per share. 3,270,330
02/28/2020 Frank A. D'Amelio
Executive Vice President
41,113   Derivative/Non-derivative trans. at $33.42 per share. 1,373,996
02/28/2020 John D. Young
Group President
51,943   Derivative/Non-derivative trans. at $36.45 per share. 1,893,322
02/28/2020 John D. Young
Group President
23,802   Derivative/Non-derivative trans. at $33.42 per share. 795,462
02/28/2020 Mikael Dolsten
President R&D
39,446   Derivative/Non-derivative trans. at $33.42 per share. 1,318,285
02/28/2020 Loretta V. Cangialosi
Sr. Vice President, Controller
14,166   Derivative/Non-derivative trans. at $36.45 per share. 516,350
02/28/2020 Loretta V. Cangialosi
Sr. Vice President, Controller
4,503   Derivative/Non-derivative trans. at $33.42 per share. 150,490
02/28/2020 Alexander Roderick MacKenzie
Executive Vice President
19,597   Derivative/Non-derivative trans. at $36.45 per share. 714,310
02/28/2020 Alexander Roderick MacKenzie
Executive Vice President
9,760   Derivative/Non-derivative trans. at $33.42 per share. 326,179
02/28/2020 Sally Susman
Executive Vice President
47,221   Derivative/Non-derivative trans. at $36.45 per share. 1,721,205
02/28/2020 Sally Susman
Executive Vice President
23,517   Derivative/Non-derivative trans. at $33.42 per share. 785,938
02/28/2020 Albert Bourla
Chairman & CEO; Director
17,118   Derivative/Non-derivative trans. at $36.45 per share. 623,951
02/28/2020 Albert Bourla
Chairman & CEO; Director
6,701   Derivative/Non-derivative trans. at $33.42 per share. 223,947
02/28/2020 Douglas M. Lankler
Executive Vice President
20,069   Derivative/Non-derivative trans. at $36.45 per share. 731,515
02/28/2020 Douglas M. Lankler
Executive Vice President
9,197   Derivative/Non-derivative trans. at $33.42 per share. 307,363
02/28/2020 Rady A. Johnson
Executive Vice President
8,264   Derivative/Non-derivative trans. at $36.45 per share. 301,222
02/28/2020 Rady A. Johnson
Executive Vice President
2,627   Derivative/Non-derivative trans. at $33.42 per share. 87,794
02/28/2020 Michael Goettler
Group President
11,805   Derivative/Non-derivative trans. at $36.45 per share. 430,292
02/28/2020 Michael Goettler
Group President
4,419   Derivative/Non-derivative trans. at $33.42 per share. 147,682
02/28/2020 Dawn Rogers
Executive Vice President
9,208   Derivative/Non-derivative trans. at $36.45 per share. 335,631
02/28/2020 Dawn Rogers
Executive Vice President
3,014   Derivative/Non-derivative trans. at $33.42 per share. 100,727
02/28/2020 Frank A. D'Amelio
Executive Vice President
173,675   Derivative/Non-derivative trans. at $27.37 per share. 4,753,484
02/28/2020 John D. Young
Group President
100,548   Derivative/Non-derivative trans. at $27.37 per share. 2,751,998
02/28/2020 Loretta V. Cangialosi
Sr. Vice President, Controller
27,422   Derivative/Non-derivative trans. at $27.37 per share. 750,540
02/28/2020 Alexander Roderick MacKenzie
Executive Vice President
37,934   Derivative/Non-derivative trans. at $27.37 per share. 1,038,253
02/28/2020 Sally Susman
Executive Vice President
91,408   Derivative/Non-derivative trans. at $27.37 per share. 2,501,836
02/28/2020 Albert Bourla
Chairman & CEO; Director
33,135   Derivative/Non-derivative trans. at $27.37 per share. 906,904
02/28/2020 Douglas M. Lankler
Executive Vice President
38,848   Derivative/Non-derivative trans. at $27.37 per share. 1,063,269
02/28/2020 Rady A. Johnson
Executive Vice President
15,996   Derivative/Non-derivative trans. at $27.37 per share. 437,810
02/28/2020 Michael Goettler
Group President
22,852   Derivative/Non-derivative trans. at $27.37 per share. 625,459
02/28/2020 Dawn Rogers
Executive Vice President
17,824   Derivative/Non-derivative trans. at $27.37 per share. 487,842
/news/latest/company/us/pfe

MarketWatch News on PFE

  1. FDA authorizes the first single-dose COVID-19 vaccine

    6:41 p.m. Feb. 27, 2021

    - Jaimy Lee

  2. J&J Covid-19 Vaccine Endorsed for Use by FDA Panel

    5:54 p.m. Feb. 26, 2021

    - Josh Nathan-Kazis

  3. Pfizer Inc. stock falls Friday, underperforms market

    5:07 p.m. Feb. 26, 2021

    - MarketWatch Automation

  4. FDA Could Approve J&J's Vaccine as Soon as Today

    8:47 a.m. Feb. 26, 2021

    - Josh Nathan-Kazis

  5. Pfizer Inc. stock outperforms market on strong trading day

    5:07 p.m. Feb. 25, 2021

    - MarketWatch Automation

  6. Pfizer Will Test Third Dose of Vaccine to Protect Against Variants

    12:40 p.m. Feb. 25, 2021

    - Josh Nathan-Kazis

  7. Loading more headlines...
/news/nonmarketwatch/company/us/pfe

Other News on PFE

  1. J&J Covid-19 Vaccine Authorized for Use in U.S.

    8:15 p.m. Feb. 27, 2021

    - Peter Loftus

  2. Dividend Champion And Contender Highlights: Week Of February 28

    1:01 p.m. Feb. 27, 2021

    - Seeking Alpha

  3. How This Income Method Makes You Financially Independent

    9:41 a.m. Feb. 27, 2021

    - Seeking Alpha

  4. Wall Street Breakfast: What Moved Markets

    8:07 a.m. Feb. 27, 2021

    - Seeking Alpha

  5. 122 Dividend Growers Include 18 Ideal Dogs For February

    2:43 p.m. Feb. 26, 2021

    - Seeking Alpha

  6. What Is Known About Virus Variants

    2:03 p.m. Feb. 26, 2021

    - Daniela Hernandez

  7. Investors Await Warren Buffett’s Annual Letter

    1:28 p.m. Feb. 26, 2021

    - Jenna Telesca

  8. Top 5 4th-Quarter Trades of Chris Davis' Firm

    11:27 a.m. Feb. 26, 2021

    - GuruFocus.com

  9. 9 Great Dividend Stocks with 3%+ Yields

    11:25 a.m. Feb. 26, 2021

    - InvestorPlace.com

  10. Health Canada authorizes AstraZeneca COVID-19 vaccine

    10:52 a.m. Feb. 26, 2021

    - Seeking Alpha

  11. What Will the Stock Market Do Today? 3 Big Stories to Watch.

    10:20 a.m. Feb. 26, 2021

    - InvestorPlace.com

  12. AT&T Carves Out Pay-TV Business in Deal With TPG

    6:43 p.m. Feb. 25, 2021

    - Drew FitzGerald

  13. Biden and Allies Stoked Vaccine Fears

    6:31 p.m. Feb. 25, 2021

    - Joel Zinberg

  14. Prometheus Biosciences Starts $125 Million IPO Plan

    4:53 p.m. Feb. 25, 2021

    - Seeking Alpha

  15. Loading more headlines...

At a Glance

Pfizer Inc.

235 East 42nd Street

New York, New York 10017-5755

Phone

1 2127332323

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$41.91B

Net Income

$6.99B

Employees

-

/news/pressrelease/company/us/pfe

Press Releases on PFE

  1. Global Liposomal Doxorubicin Market – 2019-2026

    12:14 p.m. Feb. 26, 2021

    - Heraldkeepers

  2. Loading more headlines...
Link to MarketWatch's Slice.